Get the Stockscreener App
323.86
0.24%
-0.79
After Hours:
323.87
0.010
+0.00%
Penumbra Inc stock is traded at $323.86, with a volume of 440.08K.
It is down -0.24% in the last 24 hours and down -1.97% over the past month.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
See More
Previous Close:
$324.65
Open:
$325.05
24h Volume:
440.08K
Relative Volume:
0.67
Market Cap:
$12.74B
Revenue:
$1.40B
Net Income/Loss:
$177.69M
P/E Ratio:
71.60
EPS:
4.5234
Net Cash Flow:
$174.93M
1W Performance:
-0.65%
1M Performance:
-1.97%
6M Performance:
+43.59%
1Y Performance:
+10.48%
1-Day Range:
$323.86
$325.05
1-Week Range:
$323.71
$327.44
52-Week Range:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
323.86 | 12.77B | 1.40B | 177.69M | 174.93M | 4.5234 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra earnings in focus as Boston Scientific deal looms - Investing.com
MSN Money - MSN
Vanguard Group Inc. Cuts Stock Position in Penumbra, Inc. $PEN - MarketBeat
Inside Boston Scientific's $15 billion offer for Alameda's largest employer - The Business Journals
PEN Stock Price, Quote & Chart | PENUMBRA INC (NYSE:PEN) - ChartMill
Penumbra, Inc. (NYSE:PEN) Sees Large Drop in Short Interest - MarketBeat
Vanguard Capital Management (NYSE: PEN) holds 1.99M shares, 5.07% stake - Stock Titan
[ARS] Penumbra Inc SEC Filing - Stock Titan
Penumbra (PEN) down 1.6% since last earnings report: Can it rebound? - MSN
Penumbra (NYSE: PEN) outlines 2026 meeting and $14.5B Boston Scientific sale - Stock Titan
Teacher Retirement System of Texas Reduces Stake in Penumbra, Inc. $PEN - MarketBeat
3 Reasons Why Penumbra (PEN) Is a Great Growth Stock - Yahoo Finance
Investor Outlook: Penumbra, Inc. (PEN) Eyes 10.88% Upside With Strong Revenue Growth - DirectorsTalk Interviews
Why (PEN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
How STORM-PE Thrombectomy Results and Lightning Flash Data Will Impact Penumbra (PEN) Investors - simplywall.st
Penumbra Deadline Alert - TMX Newsfile
Q3 2025 Penumbra Inc Earnings Call Transcript - GuruFocus
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
M&T Bank Corp Grows Position in Penumbra, Inc. $PEN - MarketBeat
Penumbra names Shruthi Narayan as president, effective September 1 - MSN
Penumbra (PEN) urges shareholders to approve Boston Scientific merger May 6 - Stock Titan
Boston Scientific to acquire Penumbra for enterprise value of ~$14.5B - MSN
Penumbra (PEN) Deep Dive | Q4 2025: Profit Exceeds ViewsNCAV - Xã Thanh Hà
Penumbra vote May 7 as Boston Scientific (NYSE: PEN) aims H2 2026 close - Stock Titan
Neurovascular Microcatheter Market Is Going to Boom Rapidly | Medtronic, Penumbra, Stryker - openPR.com
Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Contender With 10% Upside Potential - DirectorsTalk Interviews
Penumbra Inc stock (US70975L1070): Why Google Discover changes matter more now - AD HOC NEWS
Penumbra (PEN) Stock: Why Strong Balance Sheet (Momentum Building) 2026-04-18Rating Change - Cổng thông tin điện tử Tỉnh Sơn La
Form 425Prospectuses and communications, business combinations - ADVFN
FTC Issues Second Request for Boston Scientific and Penumbra Merger - HarianBasis.co
Penumbra Inc (NYSE:PEN) Presents a Compelling Growth and Breakout Opportunity - ChartMill
Penumbra, Inc. (NYSE:PEN) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Did STORM-PE’s Strong Functional Outcomes Just Shift Penumbra's (PEN) Investment Narrative? - Sahm
Understanding Momentum Shifts in (PEN) - Stock Traders Daily
Boston Scientific’s $14.9 Billion Bet: The Strategic "Homecoming" to Neurovascular Dominance - FinancialContent
Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A - The Chronicle-Journal
Here's Why Penumbra (PEN) is a Strong Growth Stock - Yahoo Finance
A Look At Boston Scientific (BSX) Valuation After The Penumbra Acquisition And Recent Shareholder Returns - Yahoo Finance
Penumbra (PEN) to Release Quarterly Earnings on Wednesday - MarketBeat
RBC Capital Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374 - Moomoo
Penumbra Inc stock (US70975L1070): Why its neurovascular leadership matters more now for investors - AD HOC NEWS
Penumbra Presents STORM-PE 90-day Results at SIR - dicardiology.com
Penumbra trial shows improved outcomes for pulmonary embolism By Investing.com - Investing.com Australia
Study backs Penumbra computer-assisted thrombectomy - MassDevice
Penumbra (PEN) Reports Positive Outcomes from STORM-PE Trial - GuruFocus
Aug PreEarnings: What is the long term forecast for Penumbra Inc stock2026 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):